Pfizer Inc. (NYSE: PFE) announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE